Increasing unusual call option volume: BGS IGV GPRE ZSL AXTI CARR SIRI RPRX GSK VEEV NTRA TRX STM HP
View Older Stories
-
Wells Fargo Downgrades Rapt Therapeutics (RAPT) to Equal Weight
-
Guggenheim Downgrades Rapt Therapeutics (RAPT) to Neutral
-
Clear Street Downgrades Rapt Therapeutics (RAPT) to Hold
-
GSK to acquire RAPT Therapeutics for $2.2 billion in food allergy deal
-
Shionogi Invests $2.1 bln To Raise Stake in Viiv Healthcare - Bloomberg
-
Summit Therapeutics partners with GSK for cancer drug combination trial
-
GSK (GSK) call put ratio 3.2 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
Barclays Downgrades GlaxoSmithKline (GSK) to Underweight
-
GSK receives Japan approval for asthma and nasal polyp treatment
-
GSK wins China approval for Nucala COPD treatment
-
Drugmakers Raise Us Prices On 350 Medicines Despite Pressure From Trump - Reuters
-
Samsung Biologics to buy GSK's Maryland facility for $280 million
-
14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
-
At Least 7 Drug Companies to Announce Price Cuts with Trump at White House - WaPo
-
FDA approves GSK's Exdensur for severe asthma treatment
-
GSK terminates collaboration agreement with IDEAYA Biosciences
-
UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
-
AnaptysBio files lawsuit against Tesaro and GSK over license deal
-
Bernstein on IRA pricing: $245 really is the floor
-
BofA Securities Upgrades GlaxoSmithKline (GSK) to Neutral
-
BofA Securities Upgrades GlaxoSmithKline (GSK:LN) (GSK) to Neutral
-
CFRA Upgrades GlaxoSmithKline (GSK) to Buy
-
FDA approves GSK's Blenrep for relapsed multiple myeloma treatment
-
UK closes in on drug pricing deal with White House - FT
-
ViiV Healthcare's Dovato matches Biktarvy efficacy with less weight gain
-
Trump: tariffs will get countries to agree to drug pricing plan
-
GSK receives FDA orphan drug designation for kidney disease treatment
-
Raymond James Reiterates Outperform Rating on Veeva Systems (VEEV) Amid 'Key Milestone'
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
GlaxoSmithKline (GSK) Misses Q2 EPS by 71c
-
FDA extends review period for GSK's Blenrep in multiple myeloma
-
FDA approves GSK's SHINGRIX vaccine in prefilled syringe format
-
ViiV Healthcare expands licensing deal for HIV treatment access in 133 countries
-
GSK starts shipping flu vaccines for 2025-26 season to US providers
-
GSK (GSK) spreader of 5K contracts of July 11 weekly 11 puts, July 38 puts
-
GSK (GSK) announces FDA approval of 200 mg/mL autoinjector of Benlysta
-
Bernstein: 'Why Are We Bullish on GlaxoSmithKline (GSK:LN) (GSK) ?'
-
Berenberg Downgrades GlaxoSmithKline (GSK:LN) (GSK) to Hold
-
Theravance Biopharma (TBPH) Sells Remaining Royalty Interest in Trelegy Ellipta to GSK (GSK) for $225M
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
Spero Therapeutics (SPRO) and GSK (GSK) Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy
-
GSK (GSK): Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease
-
GSK (GSK) receives FDA approval for Nucala COPD drug
-
GSK (GSK) to acquire efimosfermin
-
GlaxoSmithKline (GSK) Tops Q1 EPS by 18c
-
GSK Q1 earnings preview: 'Vaccines remain a drag' – Barclays
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
GSK's (GSK) 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices
-
BNP Paribas Exane Starts GlaxoSmithKline (GSK:LN) (GSK) at Neutral
-
Pharma stocks slide after Trump signals tariffs on sector

